Insurance

GLP-1 Prior Authorization: Step-by-Step Checklist

GLP-1 Companion · 8 min read

Almost every commercial insurance plan, Medicare Part D plan, and state Medicaid program requires prior authorization (PA) before it will cover a GLP-1 medication. Prior authorization is the process by which your insurer reviews clinical evidence to confirm that the medication is medically necessary for you before agreeing to pay for it. Although it adds steps and time, understanding the process and preparing thoroughly can turn what feels like a bureaucratic barrier into a manageable checklist.

Why GLP-1 Medications Require Prior Authorization

GLP-1 receptor agonists are among the most expensive drug classes on the market, with retail prices exceeding $900 to $1,350 per month. Insurers use prior authorization to confirm that the patient meets clinical eligibility criteria, that less expensive alternatives have been considered, and that the diagnosis code supports the prescribed indication. This process protects both the plan and, in theory, the patient from unnecessary prescriptions — though in practice it can delay access for patients with clear clinical need.

Typical Prior Authorization Criteria

Criteria vary by plan, but the following are the most commonly required thresholds based on major commercial insurer guidelines as of 2026.

• BMI of 30 kg/m² or greater (obesity, Class I or higher), OR
• BMI of 27 kg/m² or greater with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease
• Documentation that the patient has engaged in a supervised diet and exercise program for a specified period (commonly 3 to 6 months) without achieving adequate weight loss
• For some plans: prior trial and failure of at least one other anti-obesity pharmacotherapy (step therapy requirement)
• For diabetes-indicated GLP-1s (Ozempic, Mounjaro, Rybelsus): documented type 2 diabetes diagnosis with HbA1c above a plan-specific threshold (typically 7.0% to 8.0%), often combined with metformin trial
• Absence of contraindications such as personal or family history of medullary thyroid carcinoma or MEN2 syndrome

Documentation Your Prescriber Needs to Submit

The PA request is submitted by your prescriber or their office staff, not by you directly. However, you can help ensure the submission is complete by confirming that your medical record contains all the required elements before the request goes out.

• Current height, weight, and calculated BMI from a recent office visit (within the past 3 to 6 months)
• All active ICD-10 diagnosis codes for obesity and any comorbidities (E66.01 for morbid obesity due to excess calories; E11 for type 2 diabetes; I10 for essential hypertension)
• Laboratory results: HbA1c, fasting glucose, lipid panel, and kidney function if relevant
• Progress notes documenting the clinical conversation about weight management
• Records of diet and exercise counseling with dates and duration
• Documentation of any prior anti-obesity medications tried, with dosage, duration, and outcome
• For step therapy: records of the required prior therapy that was tried and discontinued
• A letter of medical necessity if required by the specific plan
• Prescriber NPI number and office contact information for follow-up

How the Prescriber Submits a Prior Authorization

Most PA requests are submitted electronically through a pharmacy benefit management portal, by fax, or through the insurer's provider portal. The pharmacy that receives your prescription will typically alert your prescriber if a PA is required before processing. Your prescriber's office staff then completes the PA request form specific to your plan and attaches supporting documentation.

1. You receive a prescription for the GLP-1 medication and attempt to fill it at your pharmacy.
2. The pharmacy checks your insurance and notifies your prescriber that a PA is required.
3. Your prescriber's office completes the insurer's PA request form and submits it with supporting clinical documentation.
4. The pharmacy benefit manager or insurer reviews the request against clinical criteria.
5. The insurer issues an approval, denial, or request for additional information within the review period.
6. Your prescriber is notified and the pharmacy is authorized to fill the prescription.

Typical Approval Timeline

Federal and state regulations set maximum review timelines for prior authorization decisions. For standard PA requests, most plans must respond within 7 to 14 calendar days, though many respond within 3 to 5 business days if the submission is complete. Expedited review — available when a delay would seriously jeopardize the patient's health — must be decided within 72 hours. If your insurer does not respond within the required window, the request may be considered approved by default under some state laws.

What to Do While Waiting for Approval

The waiting period is a good time to explore backup options so you are not left without medication if approval takes longer than expected.

• Ask your prescriber about manufacturer savings cards — some programs allow you to start at a low copay even before insurance processes the PA.
• Check whether your plan has a "provisional fill" policy that allows a short supply while the PA is under review.
• Look into patient assistance programs if cost is a concern during the review period.
• Follow up with your prescriber's office after five business days to confirm the PA was submitted and to ask for a status update.
• Ask whether your prescriber has requested a peer-to-peer review if additional clinical questions were raised.

Expedited Review for Urgent Cases

If your prescriber believes that waiting the standard review period would seriously jeopardize your health — for example, if you have rapidly worsening cardiovascular risk factors or metabolic syndrome — they can request an expedited or urgent review. This must be supported by clinical documentation and is at the prescriber's discretion to initiate. Expedited requests must receive a decision within 72 hours under federal standards.

Annual Reauthorization

Most plans require reauthorization every 12 months, even if your initial PA was approved. Reauthorization typically requires evidence that you are responding to treatment — usually measured as percentage of body weight lost, improved HbA1c, or other clinical markers. Your prescriber's office will submit updated labs and progress notes. Set a reminder approximately 60 days before your PA anniversary date so your prescriber has time to prepare the reauthorization documents before your coverage lapses.

If Your PA Is Denied

A PA denial is not final. You have the right to file an internal appeal and, if that fails, to request external independent review. The most effective appeals include a detailed prescriber letter, complete clinical documentation addressing the specific denial reason, and in many cases a peer-to-peer review between your prescriber and the insurer's medical director. See our companion guide on appealing GLP-1 insurance denials for a step-by-step walkthrough of that process.

Preparation is the single biggest factor in PA success. Prescribers whose offices submit complete, criterion-matched documentation on the first attempt have substantially higher approval rates than those who submit incomplete requests and rely on the appeals process.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.